Solid dosage form of ifosfamide
(57) Abstract:Solid legform for oral application made in the form of capsules containing mainly ifosfamide as active ingredient and microcrystalline cellulose, or made in the form of tablets containing per wt.h. the ifosfamide of 0.1 to 1.0 wt.h tricalcium phosphate and 0.04 to 0.4 wt.h. polyethylene glycol, and (based on the weight of the tablet) 5 to 60 wt. filler and regulating the flow of the additive 1 to 10 wt. carrier, 0.1 to 10 wt. supplements providing protivoukachiwauschee action, and 0.1 to 80 wt. the binder and the way his receipts. The invention relates to solid dosage forms for oral administration containing as active substance ifosfamide: 3-(2-chloroethyl)-2-(chloroethylamino)-tetrahydro-2H-1,3,2-oxazaphosphorin-2-oxide. Ifosfamide is a drug type oksazafosforina with cytostatic activity.Ifosfamide is a white crystalline powder highly hygroscopic substance with a melting point 48-51aboutC. At temperatures below the melting temperature ifosfamide begins to specalise, so it should be stored at lower temperatures. It is in the water. However, aqueous solutions can be stored for a limited time.Still the use of ifosfamide was allowed only in the form of preparations for parenteral administration. Ifosfamide is available in the form of sterile kristalliset in ampoules for injection in packaging 200-2000 mg Before using this sterile crystallised must be dissolved in water intended for injection. The concentration of such solution should not exceed 4% of the Prepared solution can be used for intravenous injection. For short-term intravenous infusion of a solution of ifosfamide dissolved in 500 ml of ringer's solution or other similar liquids for injection. The duration of infusion is usually around 30 minutes But it can last 1-2 hours In a 24-hour infusion of a solution of ifosfamide is dissolved, for example, in 3 l of 5% dextrose and salt.Upon receipt and processing of ifosfamide, there are several problems.When receiving sterile crystalline ifosfamide formed product physical characteristics which may be different. Different flowability of the obtained product, in particular, dramatically affects the accuracy and low melting point. During long-term storage sterile crystallized is sintered, the resulting decrease the rate of dissolution. With the beginning of sintering decreases pH and transparency of the resulting solution and at the same time he painted in yellow color. Usually this drug is already unsuitable for therapeutic applications.Main disadvantages associated with its use. Parenteral administration can be carried out only by qualified medical personnel. For this purpose the patient should be placed in a hospital or daily to report for treatment. This is due to time-consuming for both staff and patients.Obtain a sterile solution for injection of dry matter because of the hazard makes it necessary to take costly measures to protect personnel. For patients parenteral administration of the drug is an unpleasant procedure, as it requires to make a painful injection and infusion to connect their equipment.The result of all these shortcomings is the resulting need for preparations for oral administration, does not have these disadvantages. In oral introduction probably am the rata for oral administration failed due to physico-chemical properties of ifosfamide. Medicines in the form of soft gelatin capsules could not be obtained. Apparently, the active ingredient reacts with the shell of the capsule becomes hard, and the result is already capsule does not dissolve in the gastric juice. Similarly, numerous unsuccessful attempts to obtain tablets. Substance stuck to the stamps tabledelete machine, the resulting tablets were too soft, liquefied active substance when the compression was partially released from the matrix.The ifosfamide in a mixture with microcrystalline cellulose can be filled capsules of hard gelatin. In this case there is no undesirable interaction of ifosfamide with shell capsules. Although the shell of the capsule contains 12-15 wt. water and ifosfamide is hygroscopic and moisture sensitive material containing capsule of hard gelatin can be stored for many years and even after such long storage capsule shell dissolves in the gastric juice for a few minutes.Ifosfamide capsules in accordance with the invention contain, for example 100-800, preferably 200-500 mg ifosfamide.The contents of the capsule consists mainly of ifosfamide and mikicic regulating the fluidity and preventing the bonding additives. These control the fluidity and articleimage additives can be used both in relativity and in mixture. The total content of these additives per 1 wt. hours of ifosfamide is, for example, about 0.001 to 0.1, preferably 0.01 to 0.04 wt. 'clock as such regulating the fluidity and providing protivoukachiwauschee effect of additives can be used known additives.In particular, as these components can be used stearate and other stearates, highly dispersed silicon dioxide, stearic acid, talc and polyglycols (e.g., with a molecular weight of 4000-6000).The preferred content of regulating the flow of the additive is 0,002-0,02, most preferably 0.005 to 0,008 and additives that provide protivoukachiwauschee act of 0.004 to 0.08, and most preferably 0,016-to 0.032 wt. including 1 wt. hours of ifosfamide.In addition, the contents of the capsule may include a filler, such as starch, cellulose, lactose, fructose, sucrose, mannitol, sorbitol, calcium phosphate; binder, such as gelatin, cellulose, pectin, alginate, polyvinylpyrrolidone; media, such as alginate, carboxymethylcellulose, polyvinylpyrrolidone, ultramylonite.As is, is Aerosil), and magnesium stearate.The content of microcrystalline cellulose capsules is usually 0.2 to 4, preferably 0.25 to 1, most preferably from 0.3 to 0.35 wt. including 1 wt. hours of ifosfamide. Used microcrystalline cellulose should have a degree of crystallinity, characterized by a crystallinity index (under the crystallinity index refers to the ratio of the crystalline fraction to the total content of the crystalline and amorphous fractions. For crystalline cellulose with a particle size of about 50 μm, the value of this index is, for example, 0,71.) 0.5 and 0.9, for example, of 0.7. The degree of polymerization of microcrystalline cellulose should be in the range of 200-300. In addition, used microcrystalline cellulose must have an average grain size, for example about 50, preferably less than 50 μm. It is desirable that he was less than 40, in particular of the order of 20 microns. Preferably as microcrystalline cellulose to utilize cellulose, avicelfor example, avicelwith the distribution of particle size less than 38 microns (avicelPH 105) (this means that the average size of at least 90% of microcrystalline particles is etoc on the basis of ifosfamide as the active substance, moreover, the most appropriate was a combination of tricalcium phosphate and polyethylene glycol. Thanks to this method the first time it was possible to get such tablets by pressing on a conventional tablet press.Physico-chemical properties of ifosfamide not allow you to receive from him the tablet by pressing on normal tablemodellistener machines. All attempts of pressing of this active substance, using known auxiliary additives, such as, for example, microcrystalline cellulose, lactose, starch, talc, highly dispersed silicon dioxide, calcium phosphate, failed. And with granulation carried out in the usual way or in the fluidized bed, also failed to get the mass from which it would be easy to extrude tablets. In all cases, in the process of pressing was the adherence of the mass to the stamp or to the matrix.Tablets in accordance with the present invention per 1 wt. hours of ifosfamide contains: 0.1 to 1.0 wt. including tricalcium phosphate and 0.04 to 0.4 wt. hours of polyethylene glycol (for example, with a molecular weight of 4000-6000) and in addition (calculated on the weight of the tablet), 5-60 wt. filler and additives regulating fluidity, 1-10 wt. N. the art of ifosfamide in accordance with the invention is used, for example, 0.1 to 10 wt. hours, preferably 0.2 to 0.5, most preferably from 0.25 to 0.30 wt. including tricalcium phosphate. Based on the weight of the tablet, the amount of tricalcium phosphate is, for example, 35, preferably 7-17,8, most preferably 9-1 wt.The content of polyethylene glycol is, for example, from 0.04 to 0.4, preferably 0.1 to 0.2, most preferably of 0.13 to 0.15 wt. including 1 wt. hours of ifosfamide. It is preferable to use a polyethylene glycol with a molecular weight of 4000-6000, most preferably with a molecular weight of 6000. Based on the weight of the tablet content of polyethylene glycol is, for example, 1-14,0, preferably of 3.5 and 7.5, most preferably 4.5 to 7, in particular 4.5 to 6 wt. The weight ratio of tricalcium phosphate and polyethylene glycol is, for example, 1:0.5 in.In addition to these ingredients tablets contain: filler and regulating the flow additive in the amount of 5-60 wt. based on the weight of the tablet. As filler can be used, for example, starches, cellulose, lactose, sucrose, fructose, sorbitol, mannitol, calcium phosphate, calcium carbonate, calcium sulfate, carbonate or magnesium oxide. These compounds are used in an amount of 5-60 wt. based on the weight of the tablets.ctsu, polyglycols, starches, cellulose, talc, siliconized talc, Arahant or calcium stearate, cetyl alcohol, stearyl alcohol, ministerului alcohol, stearic acid, lauric acid. In that case, if the regulatory fluidity additive does not play simultaneously the role of filler, it is used in amount of 0.5-10 wt. based on the weight of the tablets.Media: for example alginates, starches (e.g. corn starch), pectin, carboxymethylcellulose, polyvinylpyrrolidone, ultramylonite, bentonite. Its content is 1-10 wt. based on the weight of the tablets.Supplement providing protivoukachiwauschee action, such as glycols, talc, siliconized talc, staringat talc, calcium stearate, aluminum stearate, stearic acid. Its content is 0.1-10 wt. based on the weight of the tablets.Binder, such as gelatin, a cellulose ether, amylose, pectin, cellulose, dextrose, polyglycol, tragant. Its content is 0.1-80 wt. based on the weight of the tablets.Preferably tablets, addition of ifosfamide, tricalcium phosphate and polyethylene glycol, contain the following materials: microcrystalline cellulose in an amount of 0.1 to 1.2, preferably of 0.4 to 1.0, naibolee on the weight of the tablet; lactose in the amount of 0.15 to 1.0, preferably of 0.24 and 0.68, most preferably between 0.30 and 0.40 wt. hours per weight part of ifosfamide or 5.0-36, preferably of 8.5-25 wt. based on the weight of the tablet; corn starch in the amount of 0.02-0.24 wt. hours, preferably from 0.05 to 0.20, most preferably 0.1 to 0.15 wt. hours per wt. hours of ifosfamide or 0.7 to 8.5, preferably from 2.0 to 6.5 wt. based on the weight of the tablet; talc in amounts of 0.02-0,30, preferably 0,06-0,20, most preferably 0.07 to 0.09 wt. hours per wt. hours of ifosfamide or 0.70 to 10, preferably 2 to 6,5 wt. based on the weight of the tablet; magnesium stearate in an amount of 0.004 to 0.2, preferably 0.02 to 0.12 and most preferably a 0.035 to 0.05 wt. hours per wt. hours of ifosfamide or 0.1 to 7.2, preferably 0.7 to 4.5 wt. based on the weight of the tablets.And on tablets, and capsules can be applied in a known manner the floor. It can be water-soluble, swellable, water-soluble or resistant to gastric juice coating of an aqueous dispersion or aqueous solution or dispersion in an organic solvent, such as, for example, ethanol, isopropanol, acetone, ether, dichloromethane, methanol.Capsules and tablets are temperature, eg is GNA to exceed 40%
The examples illustrate how a specific implementation of the invention.To obtain the offer in accordance with the invention, the solid dosage forms on the basis of ifosfamide for oral administration of 1 wt. hours of ifosfamide mixed with 15-30aboutWith from 0.1 to 4, preferably 0.2 to 4, most preferably 0.25 to 1 wt. including microcrystalline cellulose and, optionally, small quantities of regulating the fluidity and providing protivoukachiwauschee effect of additives to education gomogennoi mixture and this mixture is filled capsules or mix 1 wt. hours of ifosfamide with 0.1 to 1.0 wt. including tricalcium phosphate, 0.04 to 0.4 wt. hours of polyethylene glycol and 0.15 to 2, preferably 0.5 to 1.5, most preferably 1-1,3 wt. including filler and regulating the flow of the additive, of 0.03 to 0.5, preferably from 0.05 to 0.4 most preferably 0.08 to 0.2 wt. H. carrier, of 0.003 to 0.5, preferably from 0.01 to 0.4 most preferably 0.05 to 0.2 wt. including supplements, providing protivoukachiwauschee action, and 0.003 to 3, preferably from 0.01 to 2, most preferably 0.1 to 1 wt. including a binder prior to the formation of a homogeneous mixture. Then pressed from this mixture tablets and optionally applied on the obtained capsules or tablets regular floor.P R I m e R 1. Containing ifosfamide weight is the following.To obtain 12000 capsules containing the active ingredient 250 mg sift, for example, 3.0 kg of ifosfamide, 1,002 kg microcrystalline cellulose and 0,018 kg of highly disperse silicon dioxide through a sieve with a mesh size of 0.8 mm and stirred the mixture for 4 minutes in the mixer. Then to the mixture is added 0.06 kg of magnesium stearate (screened through a sieve with mesh size 0.8 mm) and stirred the mixture for another minute. The mixture is Packed in a machine for making capsules with the aspect nozzles No. 1 hard gelatin capsules of size N 1 so that each capsule contained approximately 340 mg mass.To get 20,000 capsules containing the active ingredient 500 mg sift through a sieve with a mesh size of 0.8 mm, for example, 10,0 kg ifosfamide, 3,34 kg microcrystalline cellulose and 0.06 kg of highly disperse silicon dioxide and stirred the mixture for 4 minutes in the mixer. Then to this mixture, add 0.2 kg of magnesium stearate (screened through a sieve with mesh size 0.8 mm) and stirred the mixture for one minute. Ready weight Packed on a machine for the manufacture of capsules with the aspect nozzles N 00 hard gelatin capsules size 00 so that ka is avicel PH 105, having a certain range of the distribution of particle size and representing a filler having good fluidity, which can successfully play the role of a binder.To obtain capsules resistant to gastric juice, for example at 2500 capsules of size 1 with a content of active substance (ifosfamide) 250 mg are coated with 3000 g of a suspension in an organic solvent (isopropanol). 3000 g of a suspension containing 1440 g of anionic polymerizate methacrylic acid and its esters with an average molecular weight of, for example, 150000, with the addition of the usual plasticizers, 18 g of 1,2-propane diol, 36 g of magnesium stearate and 1506 isopropanol.As copolymerizate methacrylic acid and methyl methacrylate can be used, for example, Eudragit Lin particular in the form of a 12.5% solution in isopropanol (12,5% Eudragit). Such copolymerizate soluble in the environment of neutral to slightly alkaline due to the formation of salts of alkali metals.P R I m m e R 2. Getting ifosfamide tablets.Tablets containing the active substance 250 mg can have, for example, the following composition:
One tablet weighing 700 mg contains mg: Ifosfamide 250 Melodiers LK 20 Stearate 10
To prepare the masses to get 1500 tablets 375 g of ifosfamide, 105 g of fine tricalcium phosphate, 300 g of microcrystalline cellulose, of 127.5 g of lactose, 52,5 g polyglycol 6000, 45 g of corn starch 80 g of talc pass through a sieve with a mesh size of 0.8 mm and stirred the mixture for 15 minutes in a suitable mixer. Then to the mixture is added 15 g of sifted in the same way of stearate and mix for another 2 minutes Of the cooked mass is pressed tablets on a suitable tablet press.To obtain tablets, gastro-resistant juice, 1050 g of the tablets are coated with, for example, 500 g of the aqueous dispersion of the following composition.100 g of aqueous dispersions contain, g: Polyglycol 6000 1,600 titanium Dioxide 1,100 Yellow iron oxide 0,156 Talc 4,000 Dimethylpolysiloxane 0,100 Eudragit L 30D 55,000 Water 38,044
_______< / BR>100,000
Eudragit Lis an aqueous dispersion of copolymerizate anionic character based on methacrylic acid and ethyl acrylate. The ratio of free carboxyl groups and ester groups is approximately 1:1, and the average molecular weight of about 250,000.Spraying plenkoobrazuyushchie the solvent and the dispersant is continuously removed by drying. SOLID DOSAGE FORM of IFOSFAMIDE, characterized in that the powder comprises, by weight. including the active ingredient and microcrystalline cellulose 1 - 0,2 4 for filling hard gelatin capsules and tablets contain, by weight. hIfosfamide 1,0
Tricalcium phosphate 0,1 1,0
The glycol 0,04 0,4
and auxiliary substances in the calculation of the mass of tablets, wt.Moving 5 60
Loosening 1 10
Lubricating 0.1 to 10
The binder is 0.1 to 80
Known medicinal composition of antimicrobial action, contains similar in structure with the connection 1 substance: 1-(-oxyethyl)-2-methyl-5-nitroimidazol formula:
O2N(A) called metronidazole (2)
FIELD: medicine, gastroenterology.
SUBSTANCE: one should apply food additives as tablets of oats, corn and cabbage by "Biophyt" company; moreover, to decrease motor system of biliary ducts one should apply tablets of oats, to increase motor system - tablets of corn and for total normalization of kinetics - tablets of cabbage. Treatment lasts for 10 d at the dosage of 1-2 tablets twice daily 30 min meals. The present innovation enables to normalize functional activity of biliary ducts at the background of shortened therapeutic terms.
EFFECT: higher efficiency of therapy.
FIELD: medicine, pharmacology, biochemistry, pharmacy.
SUBSTANCE: invention relates to preparations reducing blood cholesterol level. Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin and their derivatives and analogs known as inhibitors of HMG-CoA-reductase are used as anti-hypercholesterolemic agents. Above mentioned active substances can be destabilized as result of effect of environment and their destruction can be accelerated in interaction with other pharmaceutical agents, such as excipients, binding agents, lubricating agents, substances promoting to slipping and disintegrating agents. Therefore, pharmaceutical components and a method for preparing a pharmaceutical preparation must be taken thoroughly to avoid above said undesirable interactions and reactions. Invention relates to inhibitor of HMG-CoA-reductase that stabilized by formation of a homogenous composition with buffer substance or an alkalinizing substance. This homogenous composition is used as an active substance in pharmaceutical preparation used for treatment of hypercholesterolemia and hyperlipidemia. Invention enhances the enhancement of stability and homogeneity of the preparation.
EFFECT: improved and valuable pharmaceutical properties of composition.
23 cl, 2 tbl, 3 dwg, 11 ex
FIELD: medicine, pharmaceutical industry and technology, pharmacy.
SUBSTANCE: invention relates to a composition eliciting an antiviral effect. The composition comprises hydrophilic conglomerate of immunoglobulins consortium adsorbed with polyethylene glycol 4000-6000, recombinant interferon-α2 and a special additive taken among the following substances: glycine, glucose, maltose, sodium chloride taken in the definite ratio of components. Invention provides elevating solubility of composition eliciting an antiviral effect and enhanced release of biologically active substances to solution.
EFFECT: valuable medicinal properties of composition.
FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to a composition eliciting an antibacterial effect. Composition comprises hydrophilic conglomerate of immunoglobulins consortium adsorbed with polyethylene glycol 4000-6000 and a special additive taken among the following substances: glycine, glucose, maltose, sodium chloride taken in the definite ratio of components. Invention provides sufficient desorption of biologically active substances in resuspending the composition eliciting an antibacterial effect and comprising consortium of immunoglobulins.
EFFECT: valuable medicinal properties of composition.
FIELD: medicine, cardiology, pharmacy.
SUBSTANCE: invention relates to carvedilol-containing pharmaceutical composition that is used for treatment and/or prophylaxis of hypertension, cardiac insufficiency or stenocardia. The composition comprises carvedilol or its pharmaceutically acceptable salt and one or some adjuvants. Carvedilol is distributed in adjuvants as a molecular dispersion. Adjuvants are not surface-active substance and/or non-ionogenic surface-active substance. The concentration of adjuvants exceeds 5 wt.-%. Also, invention describes a method for preparing the composition and pharmaceutically acceptable solid formulation for oral administration. Compositions of the present invention provide the enhancing solubility of carvedilol and level of its absorption in lower regions of intestine.
EFFECT: improved and valuable pharmaceutical properties of composition.
17 cl, 9 ex
FIELD: medicine, antibiotics.
SUBSTANCE: invention relates to cephalosporin antibiotic - cefuroximaxetil that is used in treatment of bacterial infections. Invention proposes a new form of cefuroximaxetil not forming gel in contact with an aqueous solution. New form represents a solid solution of cefuroximaxetil in polymer and/or solid dispersion on adsorbent. New form of cefuroximaxetil can be used for preparing a granulate that can be used in oral pharmaceutical compositions as tablets or powder. Exclusion of gel-formation allows improving solubility of cefuroximaxetil that results to enhancing absorption of cefuroximaxetil in digestive tract.
EFFECT: improved pharmaceutical properties of combinations.
23 cl, 3 dwg, 8 tbl, 19 ex
SUBSTANCE: eradication of infection Heliobacter pylory in stomach comprises oral administration of corresponding drugs in powdered form mixed with orange juice. In particular, mixture of colloidal bismuth subcitrate (De-nol), Nifuratel (Macmirror), and Amoxycyllin (Flemoxin solutab) are used. Administration is performed on an empty stomach at least 30-40 min before the food intake. Patient then lies at least 30 min on the both sides alternatively.
EFFECT: suppressed water-repellent property of near-wall layer of stomach mucus and slowed down evacuation of liquid from stomach thereby ensuring fast diffusion of therapeutical substances into infect persisting zone and, therefore, direct bactericidal effect on Heliobacter pylory.
FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to an antiviral medicinal preparation. The preparation comprises ribavirin, phosphatidylcholine, cholesterol, α-tocopherol, sucrose, sodium chloride and represents lyophylizate in isotonic solution. Invention provides preparing the liposomal ribavirin eliciting high biological and therapeutic effectiveness with low toxicity.
EFFECT: improved, enhanced and valuable medicinal properties of preparation.
3 cl, 2 tbl
FIELD: chemical-pharmaceutical industry, pharmacy.
SUBSTANCE: invention relates to a new pharmaceutical preparation comprising active substance and chitosan derivative that present in nanosol in an isoionic state. Pharmaceutical preparation is prepared by the following manner: the chitosan derivative is taken to provide isoionic state at the definite level of pH value or equilibrating charges of active substance and a carrier in the preparation. An aqueous sol is prepared from chitosan derivative that contains an active substance. The pH level is regulated to provide an isoionic state at possible precipitation of colloidal particles or nanoparticles of active substance, and prepared sol is dried. Pharmaceutical preparation elicits the enhanced bioavailability, releases active substance rapidly and stable in storage.
EFFECT: improved and valuable properties of pharmaceutical preparation.
SUBSTANCE: the suggested powder consists of crystals of one component amiphostin, the length of crystalline granule corresponds to 300-700 mcm at the content of 1-3 molecule of crystalline water. In method for obtaining amiphostin powder for injections one should apply the process of vacuum drying. The innovation provides resistance of the product obtained, the crystals obtained have got moderate length and acceptable mobility without any reduction.
EFFECT: higher efficiency of application.
6 cl, 5 dwg, 13 ex, 3 tbl
FIELD: medicine, pharmacy.
SUBSTANCE: invention proposes new tablets with size less 3 mm with sustained-releasing the opioid analgesic drug for 30 min in the amount above 75%. Invention provides opioid for oral intake with taking into account individual necessity of patient due to selection of required amount of mictotablets by dispenser.
EFFECT: valuable properties of tablet, expanded assortment of medicinal formulations of opioid analgesics.
19 cl, 4 tbl, 4 ex
SUBSTANCE: invention relates to pharmaceutical compositions in the form of cellular mechanically stable, lamellar, porous, spongy or foam-like structures and to a method for their preparing from solutions and dispersions. Method involves carrying out the following stages: a) preparing a solution or homogenous dispersion liquid and compound taken among the group including one or some pharmaceutically active compounds, one or some pharmaceutically acceptable additives and their mixtures, and the following stage b) foaming solution or homogenous dispersion at reducing pressure 30-150 torrs without boiling. Invention provides stabilizing the composition.
EFFECT: improved preparing method.
38 cl, 4 ex
FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to a tablet decomposing rapidly in the buccal pocket and comprising a medicinal agent, excipient and saccharide with relatively lower melting point than that of a medicinal agent and excipient. Tablet is made by uniform mixing saccharide with low melting point with tablet mass to form bridge between particles of named medicinal agent and/or excipient through melting product followed by hardening mentioned saccharide with low melting point. Except for, invention relates to a method for making tablet decomposing rapidly in buccal pocket and comprising a medicinal agent, excipient and saccharide with relatively lower melting point than that of medicinal agent and excipient. Method involves: (a) the parent components of tablet comprising a medicinal agent, excipient and saccharide with relatively lower melting point that that of a medicinal agent and excipient are pressed under low pressure to provide the required tablet form; (b) pressed product obtained after stage (a) is heated to temperature when saccharide with low melting point is melted; (c) melted product obtained after stage (b) is cooled to temperature when melted saccharide with low melting point is hardened. Invention represents a tablet decomposing rapidly in buccal pocket and having the tablet strength providing its using in tablet-making machines for dosed formulations and giving the possibility for making tablet using common tablet-making machines, and to a method for making tablets. Except for, invention represents a tablet decomposing rapidly in buccal pocket being this table as compared with common tablets has enhanced tablet strength and improved frangibility without prolonged decomposing time in buccal pocket, and a method for tablet making.
EFFECT: improved making method.
63 cl, 4 tbl, 1 dwg, 21 ex